Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6021540 | 0.91 | STING1 (0.46) | PARP10PARP15THRATHRBPLK1 | |
| SCHEMBL6021255 | 0.91 | STING1 (0.46) | PARP10PARP15THRATHRBPLK1 | |
| SCHEMBL6020839 | 0.90 | STING1 (0.47) | PARP10PARP15THRATHRBPLK1 | |
| SCHEMBL6021329 | 0.88 | STING1 (0.47) | PARP10PARP15THRATHRBPLK1 | |
| SCHEMBL6025205 | 0.87 | HTR2A (0.39) | HTR2AHTR2CHTR2BPARP10PARP15 | |
| SCHEMBL6021022 | 0.85 | STING1 (0.49) | HTR2AHTR2CHTR2BPARP10PARP15 | |
| SCHEMBL6025152 | 0.84 | KMT2A (0.47) | THRATHRBDYRK1ASTING1 | |
| SCHEMBL6026200 | 0.84 | KMT2A (0.47) | THRATHRBDYRK1ASTING1 | |
| SCHEMBL6026767 | 0.81 | KMT2A (0.45) | STING1 | |
| SCHEMBL4762895 | 0.80 | NPC1 (0.42) | PLK1DYRK1ATDP1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664037-A1 | HALO SUBSTITUTED BENZO [B] THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | CONNOLLY MICHAEL K (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005023800-A1 | HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | HCLS1, BRI3BP, BRPF1 | HTR2A 3429/4885HTR2C 2470/4885HTR2B 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.